<DOC>
	<DOC>NCT02412423</DOC>
	<brief_summary>In "beijing model" for haploidentical transplant, the rate of acute graft-versus-host disease (GVHD) from maternal or collateral donors was significantly higher than that from other kins. To reduce the GVHD incidence from maternal or collateral donors, post-transplantation cyclophosphamide is planned to be added into the protocol in "beijing model".</brief_summary>
	<brief_title>Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors</brief_title>
	<detailed_description />
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>haploidentical patients from maternal or collateral donors uncontrolled infection before transplant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>